InvestorsHub Logo
Followers 260
Posts 18201
Boards Moderated 0
Alias Born 01/19/2006

Re: None

Friday, 03/22/2019 4:55:31 AM

Friday, March 22, 2019 4:55:31 AM

Post# of 429098
We have held shares in AVXL for many years, becoming acquainted with its molecule A-273 having potential in MS and AD; the molecule has been the subject of testing by BIIB for some time via a MTA[material transfer agreement]. We do not know whether whether Biogen became aware of any potential of Vascepa in AD; whether it knew of the VA testing of Vascepa in veterans; or whether any MTA exists that would result in Biogen having tested Vascepa in its labs also. Suffice to say, AMRN may, or may not, be the first in line for any merger with Biogen:

https://investorshub.advfn.com/boards/read_msgs.aspx?board_id=11474&NextStart=186258&BatchSize=10


http://ir.acimmune.com/phoenix.zhtml?c=254264&p=irol-irhome


https://finance.yahoo.com/news/apos-next-biogen-alzheimer-apos-160400031.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News